Standing ovation for RevMed, warning for Akeso

Scott Morgan/ASCO

Adam Feuerstein is a senior writer and biotechnology columnist, reporting on the intersection of drug development, business, Wall Street, and biotechnology. He is co-host of the weekly biotech podcast The Readout Loud and author of the newsletter Adam’s Biotech Scorecard. Signal’s Adam can be reached at stataf.54.

Matthew Harper discusses medical innovation, both its promise and its perils.

Katherine MacPhail is a reporter and editorial events programmer at STAT.

Angus reports on basic research, clinical science and drug development that have the potential to change survival and quality of life for patients, as well as developments that impact the cancer community. You can access Angus.08 on Signal.

You are reading the web version of ASCO in 30 Seconds, STAT’s guide to the American Society of Clinical Oncology Annual Meeting. Sign up for the email version here.

Oncologists can get some big applause, but they don’t give it to everyone. Today we got one of those coveted standing ovations, but the jeers and cheers didn’t stop till the end.

The plenary session may be over, but ASCO is not. Tomorrow, we will deliver the final edition of our newsletter. A virtual recap will be available on Wednesday.

STAT+ exclusive story

This article is exclusive to STAT+ subscribers

Subscribe to STAT+ for this article and daily biotech coverage and analysis.

Already have an account? Log in

Individual plan Group plan See all plans

To read the rest of this story, subscribe to STAT+.

Adam Feuerstein is a senior writer and biotechnology columnist, reporting on the intersection of drug development, business, Wall Street, and biotechnology. He is co-host of the weekly biotech podcast The Readout Loud and author of the newsletter Adam’s Biotech Scorecard. Signal’s Adam can be reached at stataf.54.
Senior Writer, Medicine, Event Editorial Director
Matthew Harper discusses medical innovation, both its promise and its perils.
reporter, live journalism
Katherine MacPhail is a reporter and editorial events programmer at STAT.
Angus reports on basic research, clinical science and drug development that have the potential to change survival and quality of life for patients, as well as developments that impact the cancer community. You can access Angus.08 on Signal.